John R. Horn, PharmD, FCCP and Philip D. Hansten, PharmD
References:
1. Corallo C, Grannell L, Tran H.
Postoperative bleeding after administration of a single dose of rivaroxaban to
a patient receiving antiretroviral therapy. Drug Saf.
2015;2:11. DOI 10.1007/s40800-015-0014-4.
2. Stollberger
C, Bastovansky A, Finsterer
J. Fatal intracerebral bleeding under rivaroxaban. Internat J Cardiol. 2015;201:110. DOI:10.1016/j.ijcard.2015.06.081.
3. Fralick M, Juurlink DN, Marras T. Bleeding
associated with coadministration of rivaroxaban and clarithromycin. CMAJ. 2016;188:669. DOI:10.1503/cmaj.150580.
4. Stollberger C, Finsterer J.
Recurrent venous thrombosis under rivaroxaban and carbamazepine for symptomatic
epilepsy. Neurol Neurochir
Pol. 2017;51:194. DOI: 0.1016/j.pjnns.2017.01.010.
5. Gordon LA,
Kumar P, Brooks, KM et al. Antiretroviral boosting agent cobicistat increases
the pharmacokinetic exposure and anticoagulant effect of dabigatran in
HIV-negative healthy volunteers. Circulation. 2016;134:1909.
DOI: 10.1161/circulationaha.116.025257.
6. Hager N, Bolt J, Albers L et al. Development of left
atrial thrombus after coadministration of dabigatran etexilate and phenytoin.
Can J Cardiol. 2017;33:554. DOI:
10.1016/j.cjca.2016.10.022.
7. Wiggins BS, Northrup A, Johnson D et al. Reduced anticoagulant
effect of dabigatran in a patient receiving concomitant phenytoin.
Pharmacotherapy. 2016;36:e5. DOI: 10.1002/phar.1698.